meteneprost and Vomiting

meteneprost has been researched along with Vomiting* in 2 studies

Trials

2 trial(s) available for meteneprost and Vomiting

Article	Year
Cervical dilatation with meteneprost vaginal suppositories in first trimester abortion. Contraception, 1986, Volume: 33, Issue:2 Forty nulliparous women were treated with vaginal suppositories containing Meteneprost (9-deoxo-16, 16-dimethyl-9-methylene PGE2) (Upjohn Co.) 10 mg or placebo prior to termination of first trimester pregnancy in a double-blind study. The suppository was inserted three hours before vacuum aspiration. The cervical diameter as measured by the size of the largest Hegar dilatator inserted without resistance was significantly larger in women treated with Meteneprost. The operative blood loss was also reduced in the Meteneprost group. Topics: 16,16-Dimethylprostaglandin E2; Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Cervix Uteri; Double-Blind Method; Female; Humans; Pregnancy; Pregnancy Trimester, First; Prostaglandins E, Synthetic; Random Allocation; Suppositories; Uterine Hemorrhage; Vacuum Curettage; Vomiting	1986
[Preoperative cervix dilatation in 1st trimester pregnancy interruption using 9-deoxy-16, 16-dimethyl-9-methylene prostaglandin E2. A randomized double-blind study]. Geburtshilfe und Frauenheilkunde, 1985, Volume: 45, Issue:8 In the double-blind study reported here the authors were able to confirm the time- and dose-related effect of dilatation of the cervix by means of the new prostaglandin-E2 derivative (9-deoxo-16, 16-dimethyl-9-methylene-PG-E2-potassium salt) as compared to placebo. In spite of the short preoperative duration of action of three hours it was observed that half of the patients treated with the prostaglandin derivative vomited once or several times. The authors therefore consider that administration of the prostaglandin vaginal suppository is only justified in cases with a high risk of cervical injury, and in primiparae undergoing termination under local anesthesia. In 38 patients termination was performed by means of direct cervicomyometrial analgesia. With one exception they approved of chemical dilatation of the cervix in spite of the side-effects, assuming that it would result in less intraoperative pain. Topics: 16,16-Dimethylprostaglandin E2; Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Cervix Uteri; Dilatation and Curettage; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Pregnancy; Prostaglandins E, Synthetic; Random Allocation; Time Factors; Vomiting	1985

Article

Year

Cervical dilatation with meteneprost vaginal suppositories in first trimester abortion.

Contraception, 1986, Volume: 33, Issue:2

Forty nulliparous women were treated with vaginal suppositories containing Meteneprost (9-deoxo-16, 16-dimethyl-9-methylene PGE2) (Upjohn Co.) 10 mg or placebo prior to termination of first trimester pregnancy in a double-blind study. The suppository was inserted three hours before vacuum aspiration. The cervical diameter as measured by the size of the largest Hegar dilatator inserted without resistance was significantly larger in women treated with Meteneprost. The operative blood loss was also reduced in the Meteneprost group.

Topics: 16,16-Dimethylprostaglandin E2; Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Cervix Uteri; Double-Blind Method; Female; Humans; Pregnancy; Pregnancy Trimester, First; Prostaglandins E, Synthetic; Random Allocation; Suppositories; Uterine Hemorrhage; Vacuum Curettage; Vomiting

1986

[Preoperative cervix dilatation in 1st trimester pregnancy interruption using 9-deoxy-16, 16-dimethyl-9-methylene prostaglandin E2. A randomized double-blind study].

Geburtshilfe und Frauenheilkunde, 1985, Volume: 45, Issue:8

In the double-blind study reported here the authors were able to confirm the time- and dose-related effect of dilatation of the cervix by means of the new prostaglandin-E2 derivative (9-deoxo-16, 16-dimethyl-9-methylene-PG-E2-potassium salt) as compared to placebo. In spite of the short preoperative duration of action of three hours it was observed that half of the patients treated with the prostaglandin derivative vomited once or several times. The authors therefore consider that administration of the prostaglandin vaginal suppository is only justified in cases with a high risk of cervical injury, and in primiparae undergoing termination under local anesthesia. In 38 patients termination was performed by means of direct cervicomyometrial analgesia. With one exception they approved of chemical dilatation of the cervix in spite of the side-effects, assuming that it would result in less intraoperative pain.

Topics: 16,16-Dimethylprostaglandin E2; Abortifacient Agents; Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Cervix Uteri; Dilatation and Curettage; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Pregnancy; Prostaglandins E, Synthetic; Random Allocation; Time Factors; Vomiting

1985